Affimed reports data from mid-stage study of its lymphoma treatment
Affimed N.V. announced data from phase 2 study of the combination of acimtamig with Artiva
Affimed N.V. announced data from phase 2 study of the combination of acimtamig with Artiva
Affimed press release (NASDAQ:AFMD): Q3 GAAP EPS of -€0.94. Revenue of €0.16M (-91.8% Y/Y). As
Affimed (NASDAQ:AFMD) is scheduled to announce Q3 earnings results on Thursday, November 14th, before market
Affimed (NASDAQ:AFMD) filed for $20M mixed securities shelf. This preliminary prospectus is not an offer
Affimed press release (NASDAQ:AFMD): Q2 GAAP EPS of -€1.01. Revenue of €0.2M (-85.7% Y/Y). As of
Summary: On 06/11/24, I published an article on Affimed focused on my belief the company’s
Affimed N.V. (NASDAQ:AFMD) has announced that Shawn M. Leland, PharmD, RPh has been appointed as Chief
Hailshadow Shares of Affimed (NASDAQ:AFMD) gained in the premarket on Wednesday after the German biotech
Affimed press release (NASDAQ:AFMD): Q1 total revenue was €0.2 million compared with €4.5 million for
Summary: Affimed’s 06/01/24 update on AFM24 means the company has a second viable commercial asset.